Posted on April 7th, 2008 by admin
By Tatum Anderson for Intellectual Property Watch
One of the most vocal voices for the interests of cancer patients in India says it will use the courts to force the Indian government to declare cancer a national emergency, in an attempt to make cancer drugs affordable to sufferers.
The Cancer Patients Aid Association (CPAA) wants the Indian [...]
No Comments »
Filed under: Campaign, News
Posted on September 11th, 2007 by admin
Even with the rejection of the appeal by from Novartis AG by the High Court in Madras on the ground that it was only an incremental innovation, the pharmaceutical companies appear to be aggressively pursuingand securingpatents for drugs that would fall under Indias frivolous patenting guidelines that bar such incremental innovations from getting patent protection.The [...]
No Comments »
Filed under: Campaign
Posted on September 1st, 2007 by admin
Times Of India
No Comments »
Filed under: Campaign, News
Posted on September 1st, 2007 by admin
By Keya Acharya , IPS news
BANGALORE, Aug 27 (IPS) – Activist groups campaigning for affordable drugs will continue their boycott campaign against Swiss pharma major Novartis AG, whose controversial petition arguing that Indian patent laws violated World Trade Organisation (WTO) provisions was rejected by the Madras High Court in southern Chennai city.
The reason for continuing [...]
No Comments »
Filed under: Campaign, News
Posted on June 19th, 2007 by admin
The case filed by the big pharmaceutical company Novartis has attracted global attention. “Doctors Without Borders” winner of the Nobel Prize for best medical relief in 1999, has requested people all over the world to write to the company to drop the case. Over two lakh people have written to Novartis. Why is this [...]
No Comments »
Filed under: Article, Campaign
Posted on March 10th, 2007 by admin
In 1997, Novartis AG filed a patent application in the Chennai ( Madras) Patent Controller’s office for the beta-crystalline of Imatinib Mesylate, brand name Glivec (Gleevec) on the ground that they invented the beta crystalline salt form (imatinib mesylate) of the free base, imatinib. In 2003, it was granted Exclusive Marketing Rights (EMR) [...]
No Comments »
Filed under: Article, Campaign, News
Posted on March 10th, 2007 by admin
Medical Patent News , March 8, 2007
A court in Chennai, India, last month heard arguments in the case regarding Novartis claims to Gleevec Patents in India. Some HIV/AIDS advocacy groups are calling on Novartis to drop its legal challenge, saying that if the company wins the case it could restrict access to antiretroviral drugs for [...]
No Comments »
Filed under: Campaign, News
